Kruszka v. Novartis Pharmaceuticals Corp.
19 F. Supp. 3d 875
D. Minnesota2014Background
- Plaintiff Candice Kruszka, diagnosed with multiple myeloma in June 2000, received IV pamidronate (Aredia) infusions from 2000–2005; branded Aredia purchases at her treatment center stopped in Jan. 2002 and generics predominated thereafter.
- After a January 2001 tooth extraction she developed persistent jaw problems; surgeons treated exposed bone, debrided necrotic bone, and pathology showed osteomyelitis; clinicians later concluded she had bisphosphonate-related osteonecrosis of the jaw (BRONJ/ONJ).
- Plaintiffs sued Novartis (manufacturer of branded Aredia) asserting strict liability, negligence (including failure to warn and design defect), breach of warranties, loss of consortium, and punitive damages.
- Novartis moved for summary judgment on multiple grounds and separately moved to exclude expert testimony (Daubert challenges) directed at causation and other topics; Plaintiffs proffered experts Drs. Marx and Kraut and relied on treating physicians Drs. Gertz and Juhlin.
- The court performed Daubert gatekeeping: it admitted much of Dr. Marx’s testimony (with limits on dose/duration and bad‑faith assertions), admitted Dr. Kraut’s specific‑causation opinion, but excluded specific‑causation testimony from treating physicians Gertz and Juhlin.
- On summary judgment the court: limited Novartis liability for post‑Jan. 2002 infusions to effects attributable to residual branded Aredia (half‑life theory) but precluded liability for injuries caused by generic pamidronates; denied summary judgment on failure‑to‑warn and punitive damages; granted summary judgment on design‑defect and implied‑warranty claims.
Issues
| Issue | Plaintiff's Argument | Defendant's Argument | Held |
|---|---|---|---|
| Admissibility of Dr. Marx (general causation, mechanism, dose/duration, bad faith) | Marx may opine on BIONJ causation, mechanisms, trial data, and dose/duration from his studies/experience | Novartis contends Marx lacks expertise/methodology for dose/duration, mechanism, and may offer improper bad‑faith opinions | Court admitted Marx on causation, mechanisms, trial patient observations, and limited dose/duration testimony to opinions grounded in specific studies; precluded bad‑faith/state‑of‑mind testimony |
| Admissibility of case‑specific experts (Drs. Kraut, Gertz, Juhlin) | Kraut, Gertz, Juhlin may each testify that Aredia caused Kruszka’s ONJ | Novartis argues Gertz/Juhlin lack reliable differential‑diagnosis methodology and Kraut ignored osteomyelitis/pathology | Court admitted Kraut’s specific‑causation opinion; excluded Gertz and Juhlin from offering specific‑causation opinions but allowed them to testify about treatment and observations |
| Liability for post‑Jan. 2002 infusions (branded v. generic) | Plaintiffs assert Novartis liable for later infusions and/or residual branded drug because of Aredia’s long half‑life | Novartis shows hospital procurement switched to generic pamidronate in Feb. 2002 and branded Aredia was not supplied after Jan. 2002 | Court held no liability for injuries caused by generics after Jan. 2002; denied summary judgment on claims tied to residual branded Aredia in Plaintiff’s system (half‑life issue remains triable) |
| Failure to warn (duty, adequacy, causation) | Novartis knew or should have known of bisphosphonate‑ONJ risk earlier and inadequate warnings caused different medical management | Novartis contends it lacked knowledge of ONJ risk during relevant treatment window and provided timely label updates starting 2003–2004 | Court found a triable issue on what Novartis knew and when, whether warnings were adequate, and whether better warnings would have changed clinical care; summary judgment denied |
| Design defect / implied warranty | Plaintiffs argue dose/duration and clinical monitoring (e.g., mouth exams) were design failures or warranty breaches | Novartis argues Plaintiffs have no evidence of a feasible alternative design or that altered dose/duration would reduce ONJ without losing efficacy; implied warranty is preempted by strict liability | Court granted summary judgment for Novartis on design‑defect (no evidence for reasonable‑care balancing/feasible safer design) and granted judgment on implied‑warranty (subsumed by strict liability) |
| Punitive damages | Plaintiffs seek punitive damages based on alleged Novartis awareness and delayed warnings | Novartis argues insufficient evidence of malicious or conscious indifference to support punitive damages | Court denied summary judgment on punitive damages, finding triable evidence that could support a punitive award under Minnesota law |
Key Cases Cited
- Daubert v. Merrell Dow Pharm., Inc., 509 U.S. 579 (1993) (trial court gatekeeping standard for expert testimony)
- Kumho Tire Co. v. Carmichael, 526 U.S. 137 (1999) (Daubert gatekeeping applies to non‑scientific expert testimony; judge has leeway in reliability inquiry)
- Gen. Elec. Co. v. Joiner, 522 U.S. 136 (1997) (court may exclude expert testimony when analytical gap between data and opinion is too great)
- Bonner v. ISP Techs., Inc., 259 F.3d 924 (8th Cir. 2001) (factual basis of expert opinion affects weight, not admissibility, absent fundamental lack of support)
- Mensing v. Wyeth, Inc., 588 F.3d 603 (8th Cir. 2009) (brand‑manufacturer liability limited for injuries caused by generic drugs in Eighth Circuit)